glp-1 cardiovascular outcomes news and mortality with receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study | Diabetologia GLP-1 Receptor Agonists in Heart

In ME/CFS and Long COVID, researchers have identified a 'mitochondrial-peroxisomal vicious cycle.' As mitochondria attempt to generate adenosine triphosphate (ATP) for energy, damaged electron transport chains 'leak' electrons, creating highly reactive superoxide radicals

The other thing is inflammation

Save with our packs

Why morning specifically

Peptide therapy is great for anyone wanting to look, feel, and perform their best

The concentration of non-HDL cholesterol (a measure of cholesterol concentration in atherogenic lipoproteins, i.e., LDL, VLDL, and so-called remnants) and apolipoprotein B may be secondary goals of therapy, especially in patients with high triglyceride concentration